Teva sets $6‑7 billion innovative medicines revenue goal for 2030 at first R&D Day
+10 new sources since this summary was written
Teva Pharmaceutical Industries announced at its inaugural R&D Day that it aims to generate between $6 billion and $7 billion in revenue from innovative medicines by 2030. President and CEO Richard Francis said the company has more than doubled innovative‑medicine revenue since launching its Pivot to Growth strategy in 2023 and plans to launch one new product each year through 2030. The firm also projected total revenue to grow at a mid‑single‑digit rate, innovative gross margins above 75%, and free cash flow exceeding $3.5 billion by 2030. The outlook was accompanied by updates on pipeline assets such as anti‑IL‑15, anti‑PD‑1/IL‑2 and next‑generation antibodies.
Why it matters
The revenue target signals a strategic shift toward higher‑margin innovative products, which could improve Teva’s profitability and cash generation. Investors will watch whether the company can sustain the projected mid‑single‑digit top‑line growth and achieve the $3.5 billion free‑cash‑flow goal, as these metrics affect credit ratings and dividend capacity.
Key facts
- 1Teva aims for $6–7 billion in innovative medicines revenue by 2030. tradingview.com
- 2Innovative medicines revenue has more than doubled since the Pivot to Growth strategy began in 2023. macaubusiness.com
- 3The company plans to launch one innovative medicine per year for the next five years. investing.com
- 4Innovative gross margins are targeted at above 75% by 2030. investing.com
- 5Total revenue is expected to grow at a mid‑single‑digit rate from 2026 to 2030. investing.com
- 6Free cash flow is projected to exceed $3.5 billion by 2030. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.